Headache & Migraine
Conference Coverage
Intranasal third-generation CGRP effective for acute migraine
Among patients taking zavegepant, more than 20% achieved pain freedom and 40% were relieved of their most bothersome symptom.
Conference Coverage
Cannabis for migraine strongly linked to rebound headache
Are patients using cannabis to treat medication overuse headache, or is cannabis contributing to the development of said headaches, or both?
Conference Coverage
Investigative gepant liver profile comparable with standard of care
The investigative oral chronic migraine therapy atogepant had 1-year side-effect and hepatic function profiles comparable with the standard of...
Conference Coverage
Rimegepant looks safe in migraine patients with cardiovascular risk
Multiple-use safety study shows similar frequency of adverse events regardless of cardiovascular risk.
Conference Coverage
Migraineurs not taking advantage of an ‘effective prophylactic’
Exercise is an underutilized resource in migraine management.
Literature Review
Ubrogepant safety and efficacy not affected by triptan therapy
The CGRP receptor antagonist shows promise, but hurdles set up by insurance companies limit its potential.
Literature Review
Green light puts the stop on migraine
Small study signals possible noninvasive approach.
Literature Review
Adherence and discontinuation limit triptan outcomes
Low rates of triptan adherence are likely caused by disappointing efficacy and/or unpleasant side effects rather than economic considerations.
From the Journals
Neurologic disorders ubiquitous and rising in the U.S.
Most of the rise in disease burden could be attributed to population aging, while age-standardized figures showed stroke and dementias to be level...
Supplements
Identifying Acute Migraine Triggers
Literature Review
The true measure of cluster headache
Patients ranked cluster headache pain higher than childbirth and kidney stones.